在慢性淋巴细胞白血病中MYC基因激活和里克特转化:与瘤微环境相互作用的联系
M Tsagiopoulou1, S Rashmi1, M Chatziaslani1,2,3
1Centro Nacional de Analisis Genomico (CNAG), Barcelona, Spain.
Frontiers in pharmacology
|September 2, 2025
概括
在侵袭性慢性淋巴细胞白血病 (CLL) 和里希特转变 (RT) 中,MYC基因活化增加. 针对MYC可能有助于对患者进行分层,并开发用于CLL进展的新疗法.
科学领域:
- 血液学
- 癌症学
- 分子生物学
背景情况:
- 慢性淋巴细胞白血病 (CLL) 具有显著的临床和生物异质性.
- 一部分CLL患者的进展为里希特转变 (RT),是一种侵袭性淋巴瘤.
- MYC基因激活与各种癌症有关,但其在CLL进展和RT中的作用需要进一步阐明.
研究的目的:
- 在CLL的不同阶段和RT中调查MYC目标基因激活.
- 确定与CLL和RT中MYC激活相关的因素.
- 探索针对MYC在CLL和RT的治疗潜力.
主要方法:
- 使用大量和单细胞RNA测序 (RNAseq) 来分析MYC目标基因表达.
- 与临床参数,基因突变 (IGHV),染色体异常 (三合体 12) 和疾病亚型相关联的MYC激活.
- 研究了MYC激活,B细胞受体信号传递,细胞循环,TLR9相互作用和瘤微环境之间的关系.
主要成果:
- 在非突变IGHV患者,三形患者和RT患者中观察到MYC激活的增加.
- 在RT中,MYC激活与B细胞受体信号独立,与细胞循环和TLR9相互作用相关.
- 高MYC激活与较短的初次治疗时间和瘤微环境中的骨髓细胞相互作用的增强相关.
结论:
- 在CLL向RT的进展中,MYC起着至关重要的作用.
- 在RT中MYC激活涉及B细胞受体信号之外的其他生存机制.
- 在CLL和RT中,MYC是患者分层和治疗发展的潜在治疗点.
相关概念视频
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
The Tumor Microenvironment
6.8K
Every normal cell or tissue is embedded in a complex local environment called stroma, consisting of different cell types, a basal membrane, and blood vessels. As normal cells mutate and develop into cancer cells, their local environment also changes to allow cancer progression. The tumor microenvironment (TME) consists of a complex cellular matrix of stromal cells and the developing tumor. The cross-talk between cancer cells and surrounding stromal cells is critical to disrupt normal tissue...
6.8K
Differentiation of Common Myeloid Progenitor Cells
3.3K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
3.3K
Mitogens and the Cell Cycle
6.6K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.6K


